… In summary, although alectinib is safer than crizotinib for patients with ALK-positive
NSCLC, its high frequency of grade 3–5 AEs should be considered during treatment. …

… This meta-analysis demonstrated that, compared to chemotherapy, treatment with crizotinib
is superior with regard to PFS in patients with non-small cell lung cancer ALK+. However, the …

… We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in
296 patients with advanced ALK-positive NSCLC who had received no previous systemic …

… lorlatinib or crizotinib in advanced ALK-positive lung cancer. … lorlatinib or crizotinib in
advanced ALK-positive lung cancer. … lorlatinib or crizotinib in advanced ALK-positive lung cancer. …

… to chemotherapy alone in this special group of patients. We hypothesized that alectinib …
be superior to chemotherapy in patients with ALK-positive NSCLC pretreated with crizotinib. …

… advanced NSCLC. Alectinib is a highly selective and potent inhibitor of ALK that is approved
for the treatment of patients with advanced ALK-positive NSCLC … are intolerant to crizotinib. …

… survival in advanced ALK-positive NSCLC has been associated with access to next-generation
ALK inhibitors, prolonged disease control with pemetrexed-based chemotherapy and …

… are required for advanced ALK-positive NSCLC. … chemotherapy-naive) ALK-positive advanced
NSCLC was demonstrated by superior progression-free survival compared with crizotinib […

… of care for ALK-positive non-small-cell lung cancer (NSCLC) [… as a treatment for advanced
ALK-positive NSCLC in Japan in … crizotinib in Japanese patients with advanced ALK-positive …

… of care for the treatment of patients with advanced ALK-positive NSCLC. … with advanced
ALK-positive NSCLC, who were chemotherapy naive or had received one prior chemotherapy …